Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Facebook X (Twitter) Instagram
Latest Headlines:
  • Nvidia’s Jensen Huang Courts Beijing Amid Renewed Market Access in China
  • Volcanic Eruption in Iceland Forces Evacuation of Tourists from Blue Lagoon as Lava Approaches Grindavik
  • Humanity Faces Significant Losses, Says Spokesperson
  • Gun Seller Backed by Donald Trump Jr. Launches Stock Trading
  • Lightning Strike in New Jersey Leaves 1 Dead, 13 Injured
  • Used EV Batteries Poised to Power AI Growth
  • UK Inflation Data Reveals Key Trends for June
  • Hijacked Small Plane Grounds Flights at Vancouver International Airport
  • Experts Warn of Vulnerabilities in Federal E-Verify System Following Workplace Raids
  • Trial Commences Over Alleged Facebook Privacy Violations Involving CEO and Others
  • Controversy Surrounds Franco-Israeli Singer Amir at Francofolies de Spa Festival
  • Newsom Criticizes Trump’s National Guard Move, Urges Maturity
  • Potential Consequences of Trump’s Dismissal of Fed Chair Powell
  • Prince Harry Honors Diana’s Legacy by Advocating Against Landmines in Angola
  • Tsunami Warning Lowered to Advisory Following 7.2 Magnitude Earthquake near Alaska
  • Goldman Sachs Reports Q2 2025 Earnings Results
  • Rubio Calls Israeli Strike on Damascus a ‘Misunderstanding’ Amid Peace Efforts
  • Complete Skeleton of Medieval Knight Discovered Beneath Former Ice Cream Parlor in Poland
  • James Gunn Discusses “Superman”: Release Date, Character’s Immigrant Story, and Themes of Kindness
  • Assembly Discusses Olive Grove; Tanal’s Brief Action Sparks Varank’s Controversial Remarks
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Sunday, August 3
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
FDA Approves Twice-Yearly Injection of HIV Prevention Drug Lenacapavir

FDA Approves Twice-Yearly Injection of HIV Prevention Drug Lenacapavir

News EditorBy News EditorJune 22, 2025 Money Watch 4 Mins Read

The U.S. Food and Drug Administration (FDA) has recently sanctioned lenacapavir, marketed as Yeztugo, as a bi-annual injection aimed at preventing HIV infection. The approval was predicated on compelling clinical trial results, indicating a remarkable 99.9% efficacy in keeping participants HIV-negative. Gilead Sciences, the manufacturer, heralded this milestone as a transformative step in combating the HIV epidemic, even as concerns loom regarding the halt of funding for HIV vaccine research.

Article Subheadings
1) FDA Approval of Lenacapavir
2) Implications for the HIV Epidemic
3) Vaccine Research Under Threat
4) Expert Insights on Vaccine Development
5) Broader Context of HIV Research Funding

FDA Approval of Lenacapavir

On Wednesday, the FDA granted approval for lenacapavir, a drug developed by Gilead Sciences, as a preventive treatment against HIV. This prescription medication, administered as an injection twice a year, is seen as a significant breakthrough in the fight against the HIV epidemic. Clinical trials supporting the approval demonstrated that 99.9% of participants who received lenacapavir remained HIV negative. The approval was influenced by robust data, emphasizing its potency and the potential to dramatically reduce new HIV infections.

Implications for the HIV Epidemic

According to recent findings from the Centers for Disease Control and Prevention (CDC), the United States recorded an estimated 31,800 new HIV infections in 2022—a worrying statistic that underscores the ongoing challenge posed by this virus. The approval of lenacapavir is anticipated to be a game-changer, with health officials calling it a major step toward controlling transmission rates. Daniel O’Day, Gilead’s CEO, characterized the decision as a “milestone moment in the decades-long fight against HIV.” His comments underscore the transformative potential of this new drug in shifting the narrative on HIV prevention.

Vaccine Research Under Threat

Despite the remarkable advancement marked by the approval of lenacapavir, there are escalating concerns about the future of HIV vaccine research. The current administration has proposed significant funding cuts to various HIV vaccine initiatives, arguing that available treatments, including lenacapavir, are sufficient. Critics of this decision contend that halting support for vaccine research is perilous, raising alarms about the prospect of a long-term solution to HIV prevention.

Expert Insights on Vaccine Development

Experts in the field have expressed mixed feelings about the approval of lenacapavir amid funding cuts to vaccine research. Dr. Barton Ford Haynes, the director of the Duke Human Vaccine Institute, described lenacapavir as a “wonderful development,” yet emphasized that the pursuit of an HIV vaccine remains critically important.

“This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials,”

said Dennis Burton, an immunology professor at Scripps Research. His sentiments reflect the urgency for continued investment in vaccine research to complement newly approved treatments.

Broader Context of HIV Research Funding

The decision to cut funding for HIV vaccine research could have far-reaching implications, hindering progress potentially for a decade. Dennis Burton cautioned that various ongoing experiments and studies could be disrupted, as research teams might be forced to pivot to unrelated areas. His comments indicate a growing concern that the short-sighted cuts to funding may stall crucial advancements in the realm of HIV vaccine development. Research on effective vaccines has seen promising leads in recent years, and the abandonment of these initiatives could have detrimental consequences in the public health landscape.

No. Key Points
1 FDA approved lenacapavir as a bi-annual injection for HIV prevention.
2 99.9% of participants in clinical trials remained HIV negative after taking the drug.
3 31,800 new HIV infections were reported in the U.S. in 2022.
4 Concerns grow regarding cuts to HIV vaccine research funding.
5 Experts emphasize the need to continue pursuing HIV vaccine development.

Summary

The FDA’s approval of lenacapavir marks a pivotal moment in the ongoing battle against HIV. With its high efficacy rate and the potential to curb new infections, it represents a significant advancement in treatment options. However, the concurrent threats to vaccine research funding pose serious challenges that could limit future progress. The dual-track approach of treatment and vaccine development remains essential in efforts to end the HIV epidemic once and for all.

Frequently Asked Questions

Question: What is lenacapavir?

Lenacapavir, marketed as Yeztugo, is a prescription medication approved by the FDA for the prevention of HIV, administered as a bi-annual injection. Clinical trials show it has a 99.9% effectiveness rate.

Question: What are the implications of the FDA’s approval of lenacapavir?

The approval is seen as a monumental step in HIV prevention, offering a new option for individuals at risk of infection and potentially reducing new case rates significantly.

Question: Why is there concern about cuts to vaccine research funding?

Cuts to vaccine research funding jeopardize ongoing studies and discourage advancements in developing a vaccine to combat HIV, which many experts believe is crucial alongside existing treatment methods.

approves Banking Budgeting Consumer Finance Credit Cards Debt Management drug Economic Indicators Economic Trends Entrepreneurship FDA Financial Literacy Financial News Financial Planning HIV Injection Investing Lenacapavir Market Analysis Money Tips Personal Finance Prevention Retirement Saving Side Hustles Stock Market TwiceYearly Wealth Management
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Money Watch

Trial Commences Over Alleged Facebook Privacy Violations Involving CEO and Others

6 Mins Read
Money Watch

Early Back-to-School Shopping Begins as Americans Aim to Avoid Tariff Effects

5 Mins Read
Money Watch

CPI Hits 2.7% Annual Rate in June, Highest Since February

6 Mins Read
Money Watch

Congress Poised to Support Stablecoins: Key Insights on Digital Currency

6 Mins Read
Money Watch

Federal Judge Overturns CFPB Rule on Medical Debt in Credit Reports: Implications Explained

5 Mins Read
Money Watch

Tax Breaks for Car Buyers Offered Under New Legislation: Here’s What to Know.

5 Mins Read
Mr Serdar Avatar

Serdar Imren

News Director

Facebook Twitter Instagram
Facebook X (Twitter) Instagram Pinterest
  • About Us
  • Get In Touch
  • Privacy Policy
  • Accessibility
  • Terms and Conditions
© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.